Pramlintide (an amylin analogue) induced migraine-like attacks in 41% of patients — similar to CGRP — suggesting amylin receptors contribute to migraine and that dual CGRP/amylin receptor antagonism could be more effective than CGRP-targeting alone.
41% migraine from amylinPramlintide triggered migraine-like attacks at rates approaching CGRP, but through different receptors — suggesting current anti-CGRP drugs miss an important migraine pathway
What the researchers found
Pramlintide induced headache in 88% and migraine-like attacks in 41% of patients (vs CGRP: 97% and 56%, differences not significant). The effects were mediated through amylin receptors, not the canonical CGRP receptor. Animal models confirmed amylin causes cutaneous hypersensitivity and light aversion.
Why it matters
Current anti-CGRP migraine drugs help many but not all patients. Identifying amylin receptor agonism as a novel migraine contributor suggests that blocking both amylin and CGRP receptors could help patients who don't respond to CGRP-targeting drugs alone.
The numbers in context
36 patients; headache 88% vs 97%; migraine 41% vs 56% (p=0.180); amylin receptor mediated; mouse: cutaneous hypersensitivity and light aversion with both amylin and CGRP
How the study worked
Randomized, double-blind, 2-way crossover clinical trial in 36 migraine without aura patients. Pramlintide or human αCGRP infusion on separate days. Supplemented with in vitro receptor pharmacology, mouse behavioral models, and tissue studies in rat, mouse, and human samples.
Who was studied
Migraine-without-aura patients in randomized crossover trial, plus mouse models
What this study cannot tell us
Moderate sample size (36 patients). Migraine provocation models may not perfectly replicate spontaneous migraine. Pramlintide is designed for diabetes, not migraine — optimal amylin receptor manipulation for migraine needs development.
How to read the evidence
High evidence: randomized, double-blind, crossover clinical trial with translational validation in cellular and animal models. Published in Annals of Neurology.
When this study was published
Published 2021. Dual CGRP/amylin receptor targeting for migraine is being explored in drug development.
The bigger picture
This study opens a new frontier in migraine treatment. Amylin and CGRP share receptor components but work through different receptors. Drugs that block both (like some next-generation therapies) could provide broader migraine relief than current CGRP-only approaches.
Questions still open
- Would dual amylin + CGRP receptor antagonists provide better migraine relief than CGRP antagonists alone?
- Does the amylin receptor contribute to CGRP-drug resistance in some patients?
- Could amylin receptor antagonists be developed as standalone migraine treatments?
Common questions
Could amylin drugs cause migraines as a side effect?
Why don't anti-CGRP drugs work for all migraine patients?
Read the original research
Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients.
Annals of neurology, 89(6), 1157-1171
Citation
Ghanizada, Hashmat; Al-Karagholi, Mohammad Al-Mahdi; Walker, Christopher S; Arngrim, Nanna; Rees, Tayla; Petersen, Jakeb; Siow, Andrew; Mørch-Rasmussen, Mette; Tan, Sheryl; O'Carroll, Simon J; Harris, Paul; Skovgaard, Lene Theil; Jørgensen, Niklas Rye; Brimble, Margaret; Waite, Jayme S; Rea, Brandon J; Sowers, Levi P; Russo, Andrew F; Hay, Debbie L; Ashina, Messoud. (2021). Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients.. Annals of neurology, 89(6), 1157-1171. https://doi.org/10.1002/ana.26072